Posted on by lowes1

CLINICAL PHARMACOLOGY STUDY OF A FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 50µg PLUS FORMOTEROL FUMARATE 6 µg VERSUS THE FREE COMBINATION OF BECLOMETHASONE HFA pMDI AND FORMOTEROL HFA pMDI AVAILABLE ON THE MARKET USING THE AEROCHAMBER PLUS™ SPACER DEVICE IN ASTHMATIC CHILDREN

Condition:   Asthma
Interventions:   Drug: CHF1535 pMDI + AC Plus;   Drug: BDP and Formoterol + AC Plus
Sponsors:   Chiesi Farmaceutici S.p.A.;   Chiesi Farmaceutici S.p.A.
Completed – verified April 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.